consistent of the direct economic burden of this disease. CONCLUSIONS: Serious economic burden has been caused by schizophrenia and increased sharply in China. Direct cost of schizophrenia is largely more than its direct cost.

PMH14
COMPARISON OF MEDICAL COSTS AND UTILIZATION ASSOCIATED WITH USE OF ZIPRASIDONE AND OLANZAPINE AMONG SCHIZOPHRENIA AND BIPOLAR DISORDER PATIENTS

University of Southern California School of Pharmacy, Los Angeles, CA, USA

OBJECTIVES: Ziprasidone is increasingly used for the treatment of schizophrenia and bipolar disorder. The purpose of this study is to compare health care costs and utilization associated with use of ziprasidone and olanzapine. METHODS: Schizophrenia and bipolar disorder patients who initiated use of ziprasidone or olanzapine between 01/2007 and 12/2010 were identified in the IMS LifeLink™ Health Plan Claims Database. Claims were desensitized into treatment episodes, and one-year costs and utilization after the initiation of episodes were analyzed. OLS regressions, general liner models, and two-part models were used to compare various types of costs associated with the use of ziprasidone and olanzapine. Logistic regressions, Poisson regressions, and Hurdle models were used to compare various types of utilization associated with use of ziprasidone and olanzapine.

RESULTS: The annual average expenditure per patient was 72881 HUF (350 USD) while the average expenditure per one inhabitant was 1352 HUF (6.5 USD). Major cost drivers were general practitioners of primary care (43.8 % of total health insurance costs), pharmaceuticals (32.2 %) and outpatient care (28.1 %). The number of patients with anxiety disease was 1014 per 100000 populations. We found the highest patient number in general practitioners of primary care (1015938 patients), pharmaceuticals (774096 patients) and outpatient care (521760 patients). CONCLUSIONS: Anxiety represents a significant burden for the health insurance system. General practitioners of primary care and pharmaceutical reimbursement are the major cost drivers for anxiety disease in Hungary.

PMH15
HEALTH INSURANCE COST OF ALZHEIMER DEMENTIA IN HUNGARY: A COST OF ILLNESS STUDY

Oberfrank F., Donka-Veres E., Boncz I.
1Institute of Experimental Medicine (IEM), Budapest, Hungary, 2Integra Consulting zrt., Budapest, Hungary, 3University of Pécs, Pécs, Hungary

OBJECTIVES: The aim of our study is to calculate the annual health insurance treatment cost of Alzheimer dementia disease in Hungary. METHODS: The data derived from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFHA), the only health care financing agency in Hungary. We analyzed the health insurance treatment cost and the number of patients for the year 2010. The following cost categories were included in the study: out-patient care, in-patient care, CT/MI, PET, home care, transportation, general practitioner, drugs and medical devices. RESULTS: The Hungarian National Health Insurance Fund Administration spent 4 426 billion Hungarian Forint (HUF) (21.266 million USD) for the treatment of Alzheimer patients. The annual average expenditure per patient was 72881 HUF (350 USD) while the average expenditure per one inhabitant was 442 HUF (2.1 USD). Major cost drivers were acute inpatient care (45.8 % of total health insurance costs), chronic inpatient care (28.1 %) and pharmaceuticals (10.4 %). The number of patients with Alzheimer disease was 60.6 per 100000 populations. We found the highest patient number in outpatient care budget (607334 patients) and pharmaceuticals (37724 patients). CONCLUSIONS: Alzheimer dementia disease represents a significant burden for the health insurance system. Hospital care (both acute and chronic) is the major cost driver for Alzheimer disease in Hungary.

PMH16
TO STUDY THE TREATMENT PATTERN AND COST OF ILLNESS IN BIPOLAR DISORDER PATIENTS IN TERTIARY CARE HOSPITAL IN SOUTH INDIA

Samajula A., Thunga G.
Manipal University, University, India

OBJECTIVES: To study the treatment pattern and cost of illness in bipolar disorder patients in tertiary care hospital in South India. METHODS: A retrospective study was conducted in a tertiary care teaching hospital of South India. Data were collected retrospectively from medical record section from 2012 to 2013 in suitable designed case record form. Data were analysed by using SPSS 20.0. RESULTS: Total of 100 cases of bipolar disorder was followed during the study period. Among them 66 were males and 34 were females. The mean age of the study population was found to be 46.2 ± 13.3 years. Among the social history 13 people were alcoholics and 60% of the study population had a family history of known psychiatric disorder. The mean duration of illness of the study population was found to be 21.8 ± 9.9 years. Among the study population 34 patients were diagnosed with mania and 46 patients diagnosed with depression. Mood examination revealed that 38 patients were happy followed by 22 patients were irritable. Affective examinations showed maximum were found in Diurnal variation (6, p < 0.001). The different treatment pattern revealed that all of them were prescribed with mood stabilizer followed by anti-psychotic (93) and hypnotics (86). The average hospitalization cost of the patient was found to be 7477.83 ± 5989.67 Rupees with median hospital stay of 7.0 days. The highest annual cost of care was $232, p < 0.001. CONCLUSIONS: Mood stabilizers and anti-psychotics were the major treatment strategies among the bipolar patients and drug cost consumes 50% of the total cost of hospitalization. Pharmacoeconomic studies play important role in estimating the total health cost burden in bipolar disorders.

PMH17
HEALTH INSURANCE COST OF ANXIETY IN HUNGARY: A COST OF ILLNESS STUDY

Oberfrank F., Donka-Veres E., Boncz I.
1Institute of Experimental Medicine (IEM), Budapest, Hungary, 2Integra Consulting zrt., Budapest, Hungary, 3University of Pécs, Pécs, Hungary

OBJECTIVES: The aim of our study is to calculate the annual health insurance treatment cost of anxiety in Hungary. METHODS: The data derive from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFHA), the only health care financing agency in Hungary. We analyzed the health insurance treatment cost and the number of patients for the year 2010. The following cost categories were included in the study: out-patient care, in-patient care, CT/MI, PET, home care, transportation, general practitioners, drugs and medical devices. RESULTS: The Hungarian National Health Insurance Fund Administration spent 13 535 billion Hungarian Forint (HUF) (65.026 million USD) for the treatment of anxiety patients. The annual average expenditure per patient was 13323 HUF (64 USD) while the average expenditure per one inhabitant was 1352 HUF (6.5 USD). Major cost drivers were general practitioners of primary care (43.8 % of total health insurance costs), pharmaceuticals (32.2 %) and outpatient care (28.1 %). The number of patients with anxiety disease was 1014 per 100000 populations. We found the highest patient number in general practitioners of primary care (1015938 patients), pharmaceuticals (774096 patients) and outpatient care (521760 patients). CONCLUSIONS: Anxiety represents a significant burden for the health insurance system. General practitioners of primary care and pharmaceutical reimbursement are the major cost drivers for anxiety disease in Hungary.

PMH18
DISEASE MANAGEMENT, RESOURCE UTILISATION AND ASSOCIATED COST FOR MODERATE AND SEVERE DEMENTIA PATIENTS IN CHINA: RESULTS FROM A DELPHI PANEL

Yan G., Le C., Clay E., Toumi M., Miles D.
1Creativ-Ceutical, London, UK, 2Lundbeck China, Beijing, China, 3Creativ-Ceutical, Paris, France, 4Department of Marseille, Marseille, Singapore

OBJECTIVES: Resulting from the scarcity of literature on dementia in China, a Delphi panel was used to obtain information on disease management, resource utilisation and associated costs for patients with moderate or severe dementia in China. METHODS: As input data, we had a economic model comparing different alternative strategies for treatment of dementia. METHODS: The Delphi panel method was used to leverage expertise of physicians involved in the treatment of dementia (Round 1 interviews with eight interviewees) and hospital administrators (Round 2 interviews with two interviewees). Final Delphi meeting gathered six experts from previous interviewees to reach a consensus. Round-1 interviews collected information on disease management, resource utilisation and economic burden of moderate and severe dementia. Round-2 interviews were based on results of Round-1 interviews to collect data on relevant costs. Interviews were done individually without sharing information from other interviewees. Results from two rounds were integrated and shared in the final Delphi discussion. A consensus was reached to obtain the final value or range of values of interest. RESULTS: Distribution of independent/ non-aggressive, independent/aggressive, dependent/non-aggressive, and dependent/ aggressive cost. The distribution was 70%, 15%, 30% and 5% at time of first diagnosis. Unit costs and resources utilisation, collected for each health state for a cycle of 6-months, showed that severe dependent/aggressive dementia patient incurred the most time from caregivers (15 hours/day). Moderate depend- ent/aggressive patients had the highest probability (90%) to be hospitalised. The average stay of hospitalisation was two months. Moderate and severe patients had the highest probability of mobility limitation (80%, 20% and 20% for each health state). CONCLUSIONS: Delphi panel results were useful for applying the data and collect data for diseases when they are not published in the literature or when automated health care databases are not available or accessible.

PMH19
COST AND RESOURCE USE OF MANAGING MAJOR DEPRESSIVE DISORDER (MDD) IN CHINA

Low W., Azmi S.Y., Lee S.L., Abdat A., Yang Y., Miles D.
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Lundbeck China, Beijing, China, 3Lundbeck Singapore Pte Ltd., Singapore

OBJECTIVES: To review studies that investigated the costs and resource use of managing major depressive disorder (MDD) in China. METHODS: A structured literature review on published articles in both English and Mandarin languages was conducted. Literature search was conducted using PubMed, Cochrane, Wan Fang, and VIP databases. Articles published between 2000 to 2013 were selected. The inclusion criteria included studies conducted in China, and studies that reported direct and indirect costs in MDD management, including factors that affected these costs, as well as resources used in managing MDD. Four reviewers (two for each language) independently selected and reviewed the articles. Direct cost included costs of MDD treatment (e.g. medication, investigation, hospitalisation, nursing care), and short-term patient care. Indirect cost was defined as the cost of premature death and indirect cost was defined as the cost of lost productivity and mortality (suicide). RESULTS: A total of 24 articles in Mandarin and English were selected and reviewed. Based on the review, direct cost for MDD reported ranged from RMB 1,000 to RMB 6,000 per patient per year, with an average direct cost of RMB 2,000 to RMB 5,000. $1M of productivity, when evaluated, accounted for more than 75% of indirect costs. Serotonin norepinephrine reuptake inhibitor (SNRI) incurred the highest direct medical cost compared to selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitor (SNRI). The annual direct cost of care had increased gradually over the years. Some of the common factors affecting the cost of MDD management included treatment duration, payment methods, types of drug prescribed, comorbidity, disease severity and social status. Studies had shown that most patients first seek treatment in general clinic or hospitals (76%)